C5orf40 Inhibitors
Inhibitors of C5orf40 function primarily by interfering with specific signaling pathways that are crucial for its activity. For instance, the MAPK/ERK and PI3K/AKT pathways, which are central to numerous cellular functions including growth and survival, can be targeted by small molecule inhibitors that prevent the phosphorylation and activation of their respective kinases. When these pathways are suppressed, the functional activity of C5orf40 may be diminished if it is normally regulated by or associated with these pathways. Similarly, inhibition of the p38 MAP kinase, which is implicated in stress responses, or the JNK pathway, associated with various regulatory processes, could lead to decreased C5orf40 activity if it is implicated in these pathways. Moreover, the disruption of mTOR signaling, a master regulator of cell metabolism, growth, and proliferation, could also result in reduced C5orf40 function if it is part of the mTOR regulatory network.
Additional pathways that provide potential targets for chemical inhibition of C5orf40 include Rho-associated protein kinase (ROCK) and BMP signaling. By selectively inhibiting ROCK, cellular processes such as shape, motility, and contraction that might be influencing C5orf40 activity can be altered, leading to its decreased function. Dorsomorphin, targeting BMP receptors, could attenuate C5orf40 activity if it is influenced by BMP-regulated pathways. Disruption of intracellular calcium levels through SERCA pump inhibition also has the potential to decrease C5orf40 activity, particularly if C5orf40 is calcium-sensitive. Furthermore, inhibiting RAF kinase, which plays a key role in the MAPK/ERK pathway, could attenuate the activity of C5orf40 if it operates downstream or is modulated by RAF kinase signaling. Finally, targeting protein kinase C (PKC) could lead to decreased C5orf40 activity, considering the breadth of cellular processes governed by PKC, including gene expression, cell cycle progression, and apoptosis, all of which might indirectly regulate C5orf40 activity.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
This compound is a selective inhibitor of mitogen-activated protein kinase kinase (MEK), which is a part of the MAPK/ERK pathway. Inhibition of this pathway can lead to reduced phosphorylation and activation of downstream targets, thereby indirectly decreasing the activity of C5orf40, which may be regulated by this pathway. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
As a potent inhibitor of the phosphoinositide 3-kinases (PI3K), LY294002 blocks the PI3K/AKT signaling pathway. This pathway is crucial for many cellular processes, including survival, and its inhibition could lead to a decrease in C5orf40 activity if C5orf40 is implicated in these survival pathways. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
Similar to PD 98059, U0126 is an inhibitor of MEK, specifically targeting MEK1 and MEK2. It prevents the activation of ERK1/2, potentially leading to reduced C5orf40 function if C5orf40 activity is associated with ERK signaling. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
This compound is a selective inhibitor of p38 MAP kinase, which is involved in inflammatory responses and stress-induced signaling. By blocking p38 MAP kinase, SB203580 might indirectly reduce the functional activity of C5orf40 if it plays a role in these signaling pathways. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
An inhibitor of c-Jun N-terminal kinase (JNK), SP600125 could lead to decreased activity of C5orf40 by inhibiting JNK-mediated signaling pathways that may be involved in the regulation of C5orf40. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a potent and irreversible inhibitor of PI3K. By inhibiting PI3K, it suppresses AKT activation and could indirectly decrease the activity of C5orf40 if C5orf40 is involved in the PI3K/AKT pathway. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
This macrolide compound inhibits the mechanistic target of rapamycin (mTOR), a key kinase in the mTOR signaling pathway. If C5orf40 activity is linked to mTOR-mediated signaling, rapamycin inhibition could lead to a decrease in C5orf40 function. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
A selective inhibitor of the Rho-associated protein kinase (ROCK), Y-27632 could indirectly inhibit C5orf40 if it is involved in ROCK-mediated signaling pathways that influence cell shape, motility, and contraction. | ||||||
BML-275 | 866405-64-3 | sc-200689 sc-200689A | 5 mg 25 mg | $94.00 $348.00 | 69 | |
This compound inhibits BMP signaling by targeting the BMP type I receptors ALK2, ALK3, and ALK6. If C5orf40 is regulated by BMP signaling, dorsomorphin could indirectly inhibit its activity. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $94.00 $349.00 | 114 | |
A SERCA pump inhibitor, thapsigargin disrupts calcium homeostasis in cells. If C5orf40 function is calcium-dependent, this disruption could lead to its decreased activity. | ||||||